J Norum

Summary

Country: Norway

Publications

  1. ncbi request reprint Chemotherapy in gastric cancer: an economic evaluation of the FAM (5-fluorouracil, adriamycin, mitomycin C) versus ELF (etoposide, leucovorin, 5-fluorouracil) regimens
    J Norum
    Department of Oncology, , Norway
    J Chemother 7:455-9. 1995
  2. ncbi request reprint Mitoxantrone in malignant pericardial effusion
    J Norum
    Department of Oncology, University Hospital of Tromsø, Norway
    J Chemother 10:399-404. 1998
  3. ncbi request reprint Prevention of colorectal cancer: a cost-effectiveness approach to a screening model employing sigmoidoscopy
    J Norum
    Department of Oncology, University Hospital of Tromsø, Norway
    Ann Oncol 9:613-8. 1998
  4. ncbi request reprint Trastuzumab in adjuvant breast cancer therapy. A model based cost-effectiveness analysis
    J Norum
    Department of Oncology, University Hospital of North Norway, Tromsø, Norway
    Acta Oncol 46:153-64. 2007
  5. ncbi request reprint Intrapleurally instilled mitoxantrone in metastatic pleural effusions: a phase II study
    U Aasebø
    Department of Pulmonary Medicine, University Hospital of Tromsø, Norway
    J Chemother 9:106-11. 1997
  6. ncbi request reprint Adjuvant cyclophosphamide, methotrexate, fluorouracil (CMF) in breast cancer--is it cost-effective?
    J Norum
    Department of Oncology, University Hospital of Tromsø, Norway
    Acta Oncol 39:33-9. 2000
  7. ncbi request reprint Quality of life in colorectal cancer patients treated with doxorubicin and a multi-drug resistance (MDR) modulator (SDZ PSC-833): a pilot study
    J Norum
    Department of Oncology, University Hospital of Tromsø, Norway
    Anticancer Res 18:2933-6. 1998
  8. pmc Evaluation of Norwegian cancer hospitals web sites and explorative survey among cancer patients on their use of the internet
    J Norum
    Norwegian Centre for Telemedicine, University Hospital of Tromsø, N 9038 Tromsø, Norway
    J Med Internet Res 3:E30. 2001
  9. ncbi request reprint Breast cancer screening by mammography in Norway. Is it cost-effective?
    J Norum
    Department of Oncology, University Hospital of Tromso, Norway
    Ann Oncol 10:197-203. 1999
  10. ncbi request reprint Screening for metastatic disease in newly diagnosed breast cancer patients. What is cost-effective?
    J Norum
    Department of Oncology, University Hospital of Tromsø, Norway
    Anticancer Res 20:2193-6. 2000

Collaborators

Detail Information

Publications14

  1. ncbi request reprint Chemotherapy in gastric cancer: an economic evaluation of the FAM (5-fluorouracil, adriamycin, mitomycin C) versus ELF (etoposide, leucovorin, 5-fluorouracil) regimens
    J Norum
    Department of Oncology, , Norway
    J Chemother 7:455-9. 1995
    ..We conclude that the standard ELF regimen too expensive in the treatment of gastric cancer...
  2. ncbi request reprint Mitoxantrone in malignant pericardial effusion
    J Norum
    Department of Oncology, University Hospital of Tromsø, Norway
    J Chemother 10:399-404. 1998
    ..Two patients are alive 213 and 294 days following therapy. Intrapericardial mitoxantrone instillation is a safe and simple way of handling MPE in malignancies sensitive to mitoxantrone...
  3. ncbi request reprint Prevention of colorectal cancer: a cost-effectiveness approach to a screening model employing sigmoidoscopy
    J Norum
    Department of Oncology, University Hospital of Tromsø, Norway
    Ann Oncol 9:613-8. 1998
    ..However, CRC is both preventable and curable. In Norway, projects aiming to detect adenomas and early cancers by the screening of a population aged about 60 years employing sigmoidoscopy have been discussed...
  4. ncbi request reprint Trastuzumab in adjuvant breast cancer therapy. A model based cost-effectiveness analysis
    J Norum
    Department of Oncology, University Hospital of North Norway, Tromsø, Norway
    Acta Oncol 46:153-64. 2007
    ..Sensitivity analyses documented survival gain, price of trastuzumab, production gain and discount rate to be the major factors influencing cost-effectiveness ratio. Trastuzumab is indicated cost effective in Norway...
  5. ncbi request reprint Intrapleurally instilled mitoxantrone in metastatic pleural effusions: a phase II study
    U Aasebø
    Department of Pulmonary Medicine, University Hospital of Tromsø, Norway
    J Chemother 9:106-11. 1997
    ..At 24 hours after instillation, mitoxantrone was only detected in circulating mononuclear cells. This study shows that mitoxantrone is efficacious in the treatment of MPE, and may represent a cost-effective alternative...
  6. ncbi request reprint Adjuvant cyclophosphamide, methotrexate, fluorouracil (CMF) in breast cancer--is it cost-effective?
    J Norum
    Department of Oncology, University Hospital of Tromsø, Norway
    Acta Oncol 39:33-9. 2000
    ..The cost per life year saved was measured as 2170- 5737. A cost-utility approach revealed a cost per quality-adjusted life year (QALY) of 2973- 7860. Adjuvant CMF in breast cancer is cost-effective in Norway...
  7. ncbi request reprint Quality of life in colorectal cancer patients treated with doxorubicin and a multi-drug resistance (MDR) modulator (SDZ PSC-833): a pilot study
    J Norum
    Department of Oncology, University Hospital of Tromsø, Norway
    Anticancer Res 18:2933-6. 1998
    ..Next to carcinoma of the bronchus, colorectal cancer (CRC) kills more people than any malignancy. Among the efforts to improve the outcome are studies on multidrug resistance (MDR) modulators combined with doxorubicin...
  8. pmc Evaluation of Norwegian cancer hospitals web sites and explorative survey among cancer patients on their use of the internet
    J Norum
    Norwegian Centre for Telemedicine, University Hospital of Tromsø, N 9038 Tromsø, Norway
    J Med Internet Res 3:E30. 2001
    ..3 million, ranks among the top countries globally for its ability to absorb and use technology. It is unclear to what degree Norwegian hospitals and patients use the Internet for information about health services...
  9. ncbi request reprint Breast cancer screening by mammography in Norway. Is it cost-effective?
    J Norum
    Department of Oncology, University Hospital of Tromso, Norway
    Ann Oncol 10:197-203. 1999
    ..Mammography screening is a promising method for improving prognosis in breast cancer...
  10. ncbi request reprint Screening for metastatic disease in newly diagnosed breast cancer patients. What is cost-effective?
    J Norum
    Department of Oncology, University Hospital of Tromsø, Norway
    Anticancer Res 20:2193-6. 2000
    ..Significant health care resources are today spent on diagnosing and treatment of early breast cancer...
  11. ncbi request reprint Health, life and disability insurance and hereditary risk for breast or colorectal cancer
    J Norum
    Department of Oncology, University Hospital of Tromsø, Norway
    Acta Oncol 39:189-93. 2000
    ..Only the major Norwegian insurer is in fact diverging in its policies...
  12. ncbi request reprint Faith among patients with advanced cancer. A pilot study on patients offered "no more than" palliation
    J Norum
    Department of Oncology, University Hospital of Tromsø, Norway
    Support Care Cancer 8:110-4. 2000
    ..The topic should be addressed in the treatment of patients with advanced disease. However, care must be taken to avoid frightening the patients. Patients' attitudes with regard to what death brings deserve respect...
  13. ncbi request reprint Intrapleural bleomycin in the treatment of chylothorax
    J Norum
    Department of Oncology, , Norway
    J Chemother 6:427-30. 1994
    ..Immediate action is necessary to prevent great loss of lipids and proteins. The underlying malignancy must be controlled to achieve a good prognosis...
  14. ncbi request reprint A monoclonal antibody against HER-2 (trastuzumab) for metastatic breast cancer: a model-based cost-effectiveness analysis
    J Norum
    Department of Oncology, University Hospital of North Norway, Tromsø, Norway
    Ann Oncol 16:909-14. 2005
    ..However, significant resources have been allocated to finance this new therapy. Due to ever increasing pressures on health care budgets, economic evaluations are requested in order to compare health effects with costs...